Revvity Inc. (NYSE:RVTY) Shares Purchased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC grew its position in Revvity Inc. (NYSE:RVTY) by 3.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 5,139 shares of the company’s stock after acquiring an additional 187 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Revvity were worth $544,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Assetmark Inc. lifted its position in Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company’s stock worth $30,000 after acquiring an additional 259 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of Revvity in the 4th quarter valued at approximately $33,000. Quarry LP increased its holdings in shares of Revvity by 45.7% in the 4th quarter. Quarry LP now owns 303 shares of the company’s stock valued at $34,000 after acquiring an additional 95 shares during the last quarter. Millstone Evans Group LLC bought a new stake in shares of Revvity in the 4th quarter valued at approximately $38,000. Finally, Vermillion Wealth Management Inc. acquired a new position in Revvity during the 4th quarter valued at approximately $41,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Stock Performance

Shares of RVTY stock opened at $101.31 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.58 and a quick ratio of 2.99. The firm has a market cap of $11.94 billion, a P/E ratio of 43.11, a PEG ratio of 2.56 and a beta of 0.98. The stock’s 50-day moving average is $94.04 and its two-hundred day moving average is $104.90. Revvity Inc. has a fifty-two week low of $87.70 and a fifty-two week high of $129.50.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.05. Revvity had a return on equity of 7.73% and a net margin of 10.35%. The business had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. During the same quarter in the prior year, the firm posted $0.98 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. Analysts predict that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be given a $0.07 dividend. The ex-dividend date is Friday, July 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. Revvity’s dividend payout ratio is currently 11.91%.

Wall Street Analyst Weigh In

RVTY has been the subject of a number of analyst reports. Wall Street Zen upgraded Revvity from a “hold” rating to a “buy” rating in a research report on Saturday, June 28th. Robert W. Baird cut their price objective on Revvity from $127.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, April 29th. The Goldman Sachs Group cut their price objective on Revvity from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 29th. Bank of America cut their target price on Revvity from $116.00 to $110.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Finally, JPMorgan Chase & Co. dropped their price target on Revvity from $120.00 to $100.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 29th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $123.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.